Xiao H Zheng

Address:

47 Newbury Ave, Quincy, MA 02171

VIN:

JTMRF4DV4A5036877

Make:

TOYOTA

Model:

RAV4

Year:

2010

US Patent:

8566628, Oct 22, 2013

Filed:

May 6, 2009

Appl. No.:

12/436439

Inventors:

Alexander Branover - Chestnut Hill MA, US
Maurice B. Steinman - Marlborough MA, US
Ming L. So - Danville CA, US
Xiao Gang Zheng - Sunnyvale CA, US

Assignee:

Advanced Micro Devices, Inc. - Sunnyvale CA

International Classification:

G06F 1/32

US Classification:

713323, 713310, 713324, 713330

Abstract:

A processor integrated circuit has one or more processor cores and a power management controller in a North-Bridge that generates a first power state recommendation for the one or more processor cores. The North-Bridge also receives a second power state recommendation from a South-Bridge integrated circuit. The North-Bridge determines a final power state for the one or more processor cores based on the first and second power state recommendations.

US Patent:

20130131035, May 23, 2013

Filed:

Feb 16, 2011

Appl. No.:

13/575912

Inventors:

Howard Bregman - Melrose MA, US
John L. Buchanan - Newton MA, US
Nagasree Chakka - Lexington MA, US
Erin F. Dimauro - Cambridge MA, US
Bingfan Du - Cambridge MA, US
Hanh Nho Nguyen - Arlington MA, US
Xiao Mei Zheng - Natick MA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07D 471/10
C07D 401/04
C07D 403/04
C07D 251/48

US Classification:

5142102, 544209, 514245, 5462681, 544323, 514275

Abstract:

The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

US Patent:

20140031340, Jan 30, 2014

Filed:

Feb 6, 2012

Appl. No.:

13/982222

Inventors:

Thomas Dineen - Somerville MA, US
Matthew Weiss - Boston MA, US
Vinod F. Patel - Acton MA, US
Xiao Mai Zheng - Natick MA, US
Ryan White - Somerville MA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07D 498/20
C07D 498/10

US Classification:

51421115, 540543

Abstract:

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I); wherein variables A, A, A, A, A, A, R, R, X and Y of Formula (I) are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and sub-formula embodiments of Formula (I) and (II), intermediates and processes and methods useful for the preparation of compounds of Formulas (I)-(II).

US Patent:

20150307521, Oct 29, 2015

Filed:

Nov 12, 2013

Appl. No.:

14/435516

Inventors:

- Thousand Oaks CA, US
Oleg EPSTEIN - Belmont MA, US
Jason B. HUMAN - Boston MA, US
Xiao Mei ZHENG - Natick MA, US
Yuan CHENG - Newbury Park CA, US
Kelvin SHAM - Thousand Oaks CA, US
Qingyian Liu - Camarillo CA, US
Ning CHEN - Thousand Oaks CA, US

International Classification:

C07D 519/00
C07D 491/052
C07D 513/20
C07D 498/10
C07D 513/10
C07D 311/80
C07D 498/20

Abstract:

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, A, A, A, A, A, L, R, R, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

US Patent:

20150266824, Sep 24, 2015

Filed:

Feb 27, 2015

Appl. No.:

14/633936

Inventors:

- Thousand Oaks CA, US
- Tokyo, JP
Howard Bregman - Melrose MA, US
Victor J. Cee - Thousand Oaks CA, US
Nagasree Chakka - Lexington MA, US
Timothy D. Cushing - Pacifica CA, US
Oleg Epstein - Belmont MA, US
Brian M. Fox - Brisbane CA, US
Stephanie Geuns-Meyer - Medford MA, US
Xiaolin Hao - Foster City CA, US
Kenta Hibiya - Chiyoda-ku, JP
Jun Kirata - Chiyoda-ku, JP
Zihao Hua - Andover MA, US
Jason Human - Boston MA, US
Shinji Kakuda - Chiyoda-ku, JP
Patricia Lopez - Woodland Hills CA, US
Ryota Nakajima - Chiyoda-ku, JP
Kazuhisa Okada - Chiyoda-ku, JP
Steven H. Olson - Millbrae CA, US
Hiroyuki Oono - Chiyoda-ku, JP
Lewis D. Pennington - Arlington MA, US
Kosuke Sasaki - Chiyoda-ku, JP
Keiko Shimada - Chiyoda-ku, JP
Youngsook Shin - Thousand Oaks CA, US
Ryan D. White - Somerville MA, US
Ryan P. Wurz - Newbury Park CA, US
Shuyan Yi - Malden MA, US
Xiao Mei Zheng - Natick MA, US

International Classification:

C07D 231/14
C07D 409/12
C07D 413/12
C07D 405/14
C07D 401/14
C07D 493/08
C07D 401/12
C07D 403/12

Abstract:

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.